Company Registration No. 05462631 (England and Wales)
RISHTON PHARMACY LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2023
PAGES FOR FILING WITH REGISTRAR
PM+M Solutions for Business LLP
Chartered Accountants
New Century House
Greenbank Technology Park
Challenge Way
Blackburn
Lancashire
BB1 5QB
RISHTON PHARMACY LIMITED
COMPANY INFORMATION
Directors
Mr B Kotecha
Mrs H Kotecha
Secretary
Mrs H Kotecha
Company number
05462631
Registered office
c/o PM+M
New Century House
Greenbank Technology Park
Challenge Way
Blackburn
Lancashire
BB1 5QB
Accountants
PM+M Solutions for Business LLP
New Century House
Greenbank Technology Park
Challenge Way
Blackburn
Lancashire
BB1 5QB
RISHTON PHARMACY LIMITED
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 6
RISHTON PHARMACY LIMITED
BALANCE SHEET
AS AT
30 APRIL 2023
30 April 2023
- 1 -
2023
2022
Notes
£
£
£
£
Fixed assets
Intangible assets
3
141,750
173,250
Tangible assets
4
53,596
63,979
Investments
5
-
0
45,000
195,346
282,229
Current assets
Stocks
30,217
22,592
Debtors
6
85,893
92,238
Cash at bank and in hand
150,834
107,078
266,944
221,908
Creditors: amounts falling due within one year
7
(151,575)
(120,876)
Net current assets
115,369
101,032
Total assets less current liabilities
310,715
383,261
Creditors: amounts falling due after more than one year
8
(22,500)
(31,500)
Provisions for liabilities
(13,399)
(12,156)
Net assets
274,816
339,605
Capital and reserves
Called up share capital
1
1
Profit and loss reserves
274,815
339,604
Total equity
274,816
339,605

The notes on pages 3 to 6 form part of these financial statements.

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 30 April 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

RISHTON PHARMACY LIMITED
BALANCE SHEET (CONTINUED)
AS AT
30 APRIL 2023
30 April 2023
- 2 -
The financial statements were approved by the board of directors and authorised for issue on 31 October 2023 and are signed on its behalf by:
Mr B Kotecha
Director
Company registration number 05462631 (England and Wales)
RISHTON PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2023
- 3 -
1
Accounting policies
Company information

Rishton Pharmacy Limited is a private company limited by shares incorporated in England and Wales. The registered office is c/o PM+M, New Century House, Greenbank Technology Park, Challenge Way, Blackburn, Lancashire, BB1 5QB.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Turnover

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

1.3
Intangible fixed assets - goodwill

Goodwill represents the excess of the cost of acquisition of unincorporated businesses over the fair value of net assets acquired. It is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is considered to have a finite useful life and is amortised on a systematic basis over its expected life, which is 20 years.

1.4
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Plant and equipment
15% on cost
Fixtures and fittings
15% on cost
Computers
20% on cost
Motor vehicles
25% on cost

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.5
Fixed asset investments

Fixed asset investments in unlisted shares are measured at fair value, with changes in fair value recognised in profit or loss if the fair value can be measured reliably. When it is not possible to measure the fair value reliably, these investments are stated at cost less impairment.

Entities in which the company has a long term interest and shares control under a contractual arrangement are classified as jointly controlled entities.

RISHTON PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 APRIL 2023
1
Accounting policies
(Continued)
- 4 -
1.6
Stocks

Stocks are stated at the lower of cost and net realisable value after making due allowance for obsolete and slow moving items.

1.7
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.8
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2023
2022
Number
Number
Total
5
5
RISHTON PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 APRIL 2023
- 5 -
3
Intangible fixed assets
Goodwill
£
Cost
At 1 May 2022 and 30 April 2023
630,000
Amortisation and impairment
At 1 May 2022
456,750
Amortisation charged for the year
31,500
At 30 April 2023
488,250
Carrying amount
At 30 April 2023
141,750
At 30 April 2022
173,250
4
Tangible fixed assets
Plant and equipment
Fixtures and fittings
Computers
Motor vehicles
Total
£
£
£
£
£
Cost
At 1 May 2022
3,228
5,318
27,484
77,425
113,455
Additions
-
0
-
0
2,583
-
0
2,583
At 30 April 2023
3,228
5,318
30,067
77,425
116,038
Depreciation and impairment
At 1 May 2022
1,753
3,763
27,164
16,796
49,476
Depreciation charged in the year
340
314
456
11,856
12,966
At 30 April 2023
2,093
4,077
27,620
28,652
62,442
Carrying amount
At 30 April 2023
1,135
1,241
2,447
48,773
53,596
At 30 April 2022
1,475
1,555
320
60,629
63,979
5
Fixed asset investments
2023
2022
£
£
Other investments other than loans
-
0
45,000
RISHTON PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 APRIL 2023
5
Fixed asset investments
(Continued)
- 6 -
Movements in fixed asset investments
Investments
£
Cost or valuation
At 1 May 2022
45,000
Disposals
(45,000)
At 30 April 2023
-
Carrying amount
At 30 April 2023
-
At 30 April 2022
45,000
6
Debtors
2023
2022
Amounts falling due within one year:
£
£
Trade debtors
54,536
43,773
Other debtors
31,357
48,465
85,893
92,238
7
Creditors: amounts falling due within one year
2023
2022
£
£
Bank loans
9,000
9,000
Trade creditors
115,610
86,691
Taxation and social security
12,898
19,001
Other creditors
14,067
6,184
151,575
120,876
8
Creditors: amounts falling due after more than one year
2023
2022
£
£
Bank loans and overdrafts
22,500
31,500
2023-04-302022-05-01false31 October 2023CCH SoftwareCCH Accounts Production 2023.200No description of principal activityMr B KotechaMrs Hemlata KotechaMrs H Kotecha054626312022-05-012023-04-3005462631bus:Director12022-05-012023-04-3005462631bus:CompanySecretaryDirector12022-05-012023-04-3005462631bus:CompanySecretary12022-05-012023-04-3005462631bus:Director22022-05-012023-04-3005462631bus:RegisteredOffice2022-05-012023-04-30054626312023-04-30054626312022-04-3005462631core:NetGoodwill2023-04-3005462631core:NetGoodwill2022-04-3005462631core:PlantMachinery2023-04-3005462631core:FurnitureFittings2023-04-3005462631core:ComputerEquipment2023-04-3005462631core:MotorVehicles2023-04-3005462631core:PlantMachinery2022-04-3005462631core:FurnitureFittings2022-04-3005462631core:ComputerEquipment2022-04-3005462631core:MotorVehicles2022-04-3005462631core:CurrentFinancialInstrumentscore:WithinOneYear2023-04-3005462631core:CurrentFinancialInstrumentscore:WithinOneYear2022-04-3005462631core:Non-currentFinancialInstrumentscore:AfterOneYear2023-04-3005462631core:Non-currentFinancialInstrumentscore:AfterOneYear2022-04-3005462631core:CurrentFinancialInstruments2023-04-3005462631core:CurrentFinancialInstruments2022-04-3005462631core:ShareCapital2023-04-3005462631core:ShareCapital2022-04-3005462631core:RetainedEarningsAccumulatedLosses2023-04-3005462631core:RetainedEarningsAccumulatedLosses2022-04-3005462631core:Goodwill2022-05-012023-04-3005462631core:PlantMachinery2022-05-012023-04-3005462631core:FurnitureFittings2022-05-012023-04-3005462631core:ComputerEquipment2022-05-012023-04-3005462631core:MotorVehicles2022-05-012023-04-30054626312021-05-012022-04-3005462631core:NetGoodwill2022-04-3005462631core:NetGoodwill2022-05-012023-04-3005462631core:PlantMachinery2022-04-3005462631core:FurnitureFittings2022-04-3005462631core:ComputerEquipment2022-04-3005462631core:MotorVehicles2022-04-30054626312022-04-3005462631core:WithinOneYear2023-04-3005462631core:WithinOneYear2022-04-3005462631core:Non-currentFinancialInstruments2023-04-3005462631core:Non-currentFinancialInstruments2022-04-3005462631bus:PrivateLimitedCompanyLtd2022-05-012023-04-3005462631bus:SmallCompaniesRegimeForAccounts2022-05-012023-04-3005462631bus:FRS1022022-05-012023-04-3005462631bus:AuditExemptWithAccountantsReport2022-05-012023-04-3005462631bus:FullAccounts2022-05-012023-04-30xbrli:purexbrli:sharesiso4217:GBP